Fig. 12

AT9283 suppresses the tumor growth and DLGAP5/PLK1 axis in a murine LUAD xenograft model. A Schematic illustration of the in vivo experimental design. Female BALB/c nude mice (n = 5) bearing H1299 cells were intraperitoneally treated with AT9283 (20 mg/kg) daily for 5 days followed by a two-day break for a period of 3 weeks, then tumors were harvested for analysis. B Photos of the formed tumors at the end of experiments. C Tumor weight at the end of experiments. Data are presented as mean ± SD, ^**P < 0.01. D Tumor growth curve. Data are presented as mean ± SD, ^**P < 0.01. E The formed tumors were collected for detection of DLGAP5 and PLK1 by western blot assay. F Schematic diagram of possible action mechanism by which AT9283 plays a role in LUAD growth